iRadimed (NASDAQ:IRMD) Issues Q2 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its second quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.440-0.480 for the period, compared to the consensus EPS estimate of 0.460. The company issued revenue guidance of $20.0 million-$21.0 million, compared to the consensus revenue estimate of $21.1 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $120.00.

iRadimed Price Performance

Shares of NASDAQ IRMD traded up $3.71 during midday trading on Friday, hitting $87.15. 346,336 shares of the company’s stock were exchanged, compared to its average volume of 103,465. iRadimed has a twelve month low of $50.31 and a twelve month high of $107.90. The company has a market cap of $1.11 billion, a PE ratio of 49.80 and a beta of 1.11. The firm’s fifty day simple moving average is $96.69 and its 200-day simple moving average is $93.87.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts anticipate that iRadimed will post 1.94 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is 45.71%.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 3,750 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at approximately $196,040,550. This trade represents a 0.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,750 shares of company stock worth $4,708,950. 36.80% of the stock is currently owned by company insiders.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in iRadimed during the third quarter worth approximately $40,000. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Virtus Advisers LLC acquired a new position in iRadimed during the third quarter worth approximately $117,000. Aquatic Capital Management LLC increased its position in iRadimed by 210,400.0% during the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 2,104 shares during the period. Finally, Quantbot Technologies LP acquired a new position in iRadimed during the third quarter worth approximately $164,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.